BSX — Boston Scientific Corporation

Boston Scientific Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $5.203 billion, an increase of 11.6% year-over-year, including a 220 basis point boost from foreign exchange.
• Organic Revenue Growth: 9.4%, in line with guidance of 8.5% to 10%.
• Adjusted EPS: $0.80, up 6% year-over-year, achieving the high end of the guidance range ($0.78 to $0.80).
• Adjusted Operating Margin: 28.8%, with a GAAP operating margin of 21.2%.
• Free Cash Flow: $170 million, with expectations of approximately $4 billion for the full year.
• Cash on Hand: $1.453 billion, with a gross debt leverage ratio of 1.8x.

2. Strategic Updates and Business Highlights

• U.S. Growth: 11% with double-digit growth in five out of eight business units.
• Key Products: Strong performance from FARAPULSE, WATCHMAN, and Neuromodulation therapies.
• International Growth: Asia Pacific grew 12%, with notable performance in Japan and China.
• Urology Challenges: Urology sales grew only 1%, affected by issues in stone management and neuromodulation.
• Acquisitions: Completed acquisition of Valencia Technologies and anticipate closing the Penumbra deal in the second half of 2026.

3. Forward Guidance and Outlook

• Q2 2026 Guidance: Organic growth expected between 5% and 7%.
• Full Year 2026 Guidance: Adjusted down to 6.5% to 8% organic growth, with adjusted EPS projected between $3.34 and $3.41 (growth of 9% to 11%).
• WATCHMAN Growth: Expected to be mid-teens globally, with U.S. growth anticipated to be low to mid-teens.

4. Bad News, Challenges, or Points of Concern

• Guidance Reduction: Full-year guidance lowered due to unexpected headwinds in EP, WATCHMAN, and Urology.
• WATCHMAN Volume Decline: Notable deceleration in stand-alone WATCHMAN procedures, attributed to evolving practice patterns and hospital capacity issues.
• Urology Underperformance: Sales growth fell short of expectations, with challenges in the stone management segment and commercial disruptions in neuromodulation.
• Competitive Pressures: Increased competition in the EP market, leading to greater share erosion than anticipated.

5. Notable Q&A Insights

• Management's Confidence: Despite challenges, management remains confident in long-term growth and the potential for recovery in 2027, supported by new product launches.
• Operational Adjustments: Plans to enhance commercial focus on WATCHMAN and improve operational efficiencies in response to recent challenges.
• Market Dynamics: Discussion highlighted the shift towards concomitant procedures over stand-alone WATCHMAN cases, necessitating adjustments in marketing and sales strategies.
• Future Product Launches: Emphasis on upcoming product launches in 2026 and 2027 as key drivers for growth, particularly in EP and Urology.

Overall, while Boston Scientific reported solid Q1 results, the company faces significant challenges that have led to a cautious outlook for the remainder of 2026. Management is focused on addressing these issues while positioning for future growth through strategic investments and product innovation.